NASDAQ:MRNS
Marinus Pharmaceuticals Stock News
$1.30
-0.0300 (-2.26%)
At Close: May 16, 2024
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
08:38pm, Monday, 23'rd Mar 2020
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announc
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 56'5(C)(4)
12:00am, Monday, 23'rd Mar 2020Marinus Pharmaceuticals to host a virtual special shareholder meeting MRNS
07:39am, Friday, 20'th Mar 2020
Marinus Pharmaceuticals to host a virtual special shareholder meeting MRNS
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications
11:30am, Thursday, 19'th Mar 2020
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced the appointment of Sasha Damou
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis As Vice President, Investor Relations And Corporate Communications
12:00am, Thursday, 19'th Mar 2020Will Marinus Pharmaceuticals (NASDAQ:MRNS) Spend Its Cash Wisely?
12:19pm, Wednesday, 18'th Mar 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
18 Healthcare Stocks Moving In Tuesday's Pre-Market Session
12:58pm, Tuesday, 17'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX
Marinus (MRNS) Receives a Buy from Oppenheimer
09:12pm, Monday, 16'th Mar 2020
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Marinus (MRNS), with a price target of $6.00. The company's shares
Marinus (MRNS) Receives a Buy from Oppenheimer
09:12pm, Monday, 16'th Mar 2020
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Marinus (MRNS – Research Report), with
Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results
11:30am, Monday, 16'th Mar 2020
RADNOR, Pa., March 16, 2020 -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare.
ABEV, PLAN among premarket losers
02:17pm, Thursday, 27'th Feb 2020
Anaplan (NYSE:PLAN) -29% despite Q4 beat.Continental Resources (NYSE:CLR) -26% on Q4 earnings.Nutanix (NASDAQ:NTNX) -20% on Q2 earnings.Virgin Galactic Holdings (NYSE:SPCE) -18% after pair of
